Clinical Practice Guidelines for the management of locally advanced ...

91. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant
hormone therapy for localised and locally advanced prostate cancer. Cochrane Database of
Systematic Reviews 2006;(4):CD006019.
92. Pilepich MV, Winter K, John MJ et al. Phase III radiation therapy oncology group (RTOG) trial
86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced
carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics
50(5):1243-52, 2001.
93. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced
prostate cancer treated with radiotherapy and goserelin. New England Journal of Medicine
337(5):295-300, 1997.
94. Tyrrell CJ, Payne H, See WA et al. Bicalutamide ('Casodex') 150 mg as adjuvant to
radiotherapy in patients with localised or locally advanced prostate cancer: results from the
randomised Early Prostate Cancer Programme. Radiotherapy & Oncology 76(1):4-10, 2005.
95. Lawton CA, Bae K, Pilepich M, Hanks G, Shipley W. Long-term treatment sequelae after
external beam irradiation with or without hormonal manipulation for adenocarcinoma of the
prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02. Int J
Radiat Oncol Biol Phys 2008;70(2):437-441.
96. Pilepich MV, Buzydlowski JW, John MJ, Rubin P, McGowan DG, Marcial VA. Phase II trial
of hormonal cytoreduction with megestrol and diethylstilbestrol in conjunction with
radiotherapy for carcinoma of the prostate: outcome results of RTOG 83-07. Int J Radiat Oncol
Biol Phys 1995;32(1):175-180.
97. Hanks GE, Pajak TF, Porter A et al. Phase III trial of long-term adjuvant androgen deprivation
after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of
the prostate: the Radiation Therapy Oncology Group Protocol 92-02.[erratum appears in J Clin
Oncol. 2004 Jan 15;22(2):386]. Journal of Clinical Oncology 21(21):3972-8, 2003.
98. Asbell SO, Leon SA, Tester WJ, Brereton HD, Ago CT, Rotman M. Development of anemia
and recovery in prostate cancer patients treated with combined androgen blockade and
radiotherapy. Prostate 29(4):243-8, 1996.
99. Clark T, Parekh DJ, Cookson MS et al. Randomized prospective evaluation of extended versus
limited lymph node dissection in patients with clinically localized prostate cancer. J Urol
2003;169(1):145-147.
100. Thomas DJ, Balaji VJ, Coptcoat MJ, Abercrombie GF. Acute urinary retention secondary to
carcinoma of the prostate. Is initial channel TURP beneficial? J R Soc Med 1992;85(6):318-
319.
101. Messing EM, Manola J, Yao J et al. Immediate versus deferred androgen deprivation treatment
in patients with node-positive prostate cancer after radical prostatectomy and pelvic
lymphadenectomy. Lancet Oncology 7(6):472-9, 2006.
102. Bolla M, Van Poppel H, Collette L et al. Postoperative radiotherapy after radical prostatectomy:
a randomised controlled trial (EORTC trial 22911). Lancet 366(9485):572-8, 2005.
103. Swanson GP, Thompson IM, Tangen C et al. Phase II randomized study of adjuvant radiation
therapy versus observation in pathients with pathologic T3 prostate cancer (SWOG 8794).
International Journal of Radiation Biology 2005;63 (Supplement 1):S1.
104. Thompson IM, Jr., Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathologically
advanced prostate cancer: a randomized clinical trial. JAMA 2006;296(19):2329-2335.
Clinical practice guidelines for the management of locally advanced and metastatic prostate cancer
46